On Thursday, GN Hearing has released its full-year figures for 2021 and its 2022 outlook. The hearing aid manufacturer expects to grow organically by 5–10 percent with an EBITA margin of 14 percent in the current financial year.
by christopher due karlsson, translated by daniel pedersen
On Thursday morning, hearing aid manufacturer GN Hearing has released its full-year figures for 2021 and in connection with the report comes the company’s 2022 outlook.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.